抗凝管理:当前景观和未来趋势
Andaleb Kholmukhamedov1, David Subbotin2, Anna Gorin3
1Versiti Blood Research Institute, Milwaukee, WI 53226, USA.
Journal of clinical medicine
|March 17, 2025
概括
抗凝剂可以防止危险的血栓形成. 本综述涵盖了它们的历史,当前使用和未来,包括新型XIa因子抑制剂和用于个性化治疗的AI.
科学领域:
- 药理学 药理学 是一个学科.
- 血液学 血液学 血液学
- 医学科学 医学科学 医学科学
背景情况:
- 血液在营养物质运输,氧气输送,废物清除和血液静止中的作用.
- 血栓形成,在血管中形成异常的血块,导致心脏病发作,中风和肺栓塞.
- 抗凝剂对于预防和治疗血栓形成至关重要.
研究的目的:
- 为了回顾抗凝剂的历史发展.
- 讨论抗凝固药治疗当前的临床应用和挑战.
- 探索未来的趋势,包括新型药物和人工智能在血栓形成管理.
主要方法:
- 对抗凝血剂的文献审查.
- 对抗凝血剂发现和使用的历史数据的分析.
- 检查当前的治疗策略和新兴技术.
主要成果:
- 抗凝剂已经从早期的药物,如肝素,演变为现代的直接口服抗凝剂 (DOAC).
- 目前的抗凝剂包括维生素K对抗剂 (VKA),肝素和DOAC,每个都有特定的应用.
- 由于患者的变化和平衡血栓形成预防与出血风险,治疗管理是复杂的.
结论:
- 抗凝剂治疗对于治疗血栓状况至关重要,特别是在老年人群中.
- 未来的方向包括XIa因子抑制剂用于降低出血风险的有针对性的血栓形成预防.
- 人工智能为个性化抗凝药疗法和改善患者治疗结果提供了潜力.
相关概念视频
Current Trends in Nursing I
1.4K
Current trends in nursing include:
1.4K
Current Trends in Nursing II
1.2K
Trends in nursing are multifactorial and associated with changes in society, within the nursing profession, and in other professions. Notably, telehealth and remote nursing contribute to successful healthcare delivery for numerous patients and help reduce stress for nurses due to nursing shortages. Nurses can reach patients, monitor their conditions, and interact with them using computers, audio, visual accessories, and telephones—for example, remote patient monitoring systems. Likewise,...
1.2K
Issues And Trends In Healthcare Delivery System
5.5K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
585
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
585
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
441
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
441


